The Role of the Amadori Product in the Complications of Diabetes
Ina Nemet
Pathology
Division of Organic Chemistry and Biochemistry, Rudjer Boskovic Institute, Zagreb, Croatia
Search for more papers by this authorJianye Zhang
Chemistry, Case Western Reserve University, Cleveland, Ohio, USA
Search for more papers by this authorIna Nemet
Pathology
Division of Organic Chemistry and Biochemistry, Rudjer Boskovic Institute, Zagreb, Croatia
Search for more papers by this authorJianye Zhang
Chemistry, Case Western Reserve University, Cleveland, Ohio, USA
Search for more papers by this authorAbstract
Strong evidence has emerged in recent years in support of an association between advanced glycation and the complications of diabetes, whereby both glycoxidation products and oxoaldehydes have been implicated. In contrast, except for the fact that skin collagen-linked fructosamine (Amadori product) is a strong predictor of the risk of progression of microvascular disease in humans, Amadori products have not been associated with complications in most animal experiments. Below we develop the hypothesis that glucose-derived advanced glycation end products (AGEs), such as glucosepane, may inflict sustained damage to the extracellular matrix in diabetes and contribute to tissue stiffening and accelerated sclerosis in arteries, kidneys, and other organs as supported by immunochemical studies using a glucosepane antibody. We also hypothesize that many more structures derived from Amadori products with nucleophiles, such as primary amines and thiols, are expected. The selective prevention of Amadori-derived AGEs using deglycating enzymes would be desirable. However, x-ray diffraction studies of Amadoriase I crystals show that the active site of the enzyme is deeply embedded, explaining why this approach is unlikely to succeed in vivo. Preliminary experiments with nucleophiles show that aminoguanidine and other compounds block glucosepane in vitro.
References
- 1 Monnier, V.M. 2003. Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys. 419: 1–15.
- 2 Genuth, S. et al. 2005. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54: 3103–3111.
- 3 Herold, K. et al. 2007. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol. 82: 204–212.
- 4 Chuang, P.Y. et al. 2007. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 72: 965–976.
- 5 Dobler, D. et al. 2006. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 55: 1961–1969.
- 6 Uribarri, J. et al. 2007. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30: 2579–2582.
- 7 Grant, P.J. 2007. Diabetes mellitus as a prothrombotic condition. J. Intern. Med. 262: 157–172.
- 8 Williams, S.K. et al. 1982. Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc. Natl. Acad. Sci. USA 79: 6546–6550.
- 9 Harding, J.J. & E. Ganea. 2006. Protection against glycation and similar post-translational modifications of proteins. Biochim. Biophys. Acta 1764: 1436–1446.
- 10 Bolton, W.K. et al. 2004. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24: 32–40.
- 11 Metz, T.O. et al. 2003. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys. 419: 41–49.
- 12 Metz, T.O. et al. 2003. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J. Biol. Chem. 278: 42012–42019.
- 13 Price, D.L. et al. 2001. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276: 48967–48972.
- 14 Rahbar, S. 2007. Novel inhibitors of glycation and AGE formation. Cell. Biochem. Biophys. 48: 147–157.
- 15 Nagai, R. et al. 2007. Succination of protein thiols during adipocyte maturation—a biomarker of mitochondrial stres. J. Biol. Chem. 282: 34219–34228.
- 16 Figarola, J.L. et al. 2003. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46: 1140–1152.
- 17 Ruggiero-Lopez, D. et al. 1999. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 58: 1765–1773.
- 18 Izuhara, Y. et al. 2005. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J. Am. Soc. Nephrol. 16: 3631–3641.
- 19 Thornalley, P.J. 2007. Endogenous alpha-oxoaldehydes and formation of protein and nucleotide advanced glycation endproducts in tissue damage. Novartis Found Symp. 285: 229–243.
- 20 Kennedy, L. & J.W. Baynes. 1984. Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 26: 93–98.
- 21 Veiga da-Cunha, M. et al. 2006. Increased protein glycation in fructosamine 3-kinase-deficient mice. Biochem. J. 399: 257–264.
- 22 Sell, D.R. et al. 2005. Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. J. Biol. Chem. 280: 12310–12315.
- 23 Ahmed, M.U., S.R. Thorpe & J.W. Baynes. 1986. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem. 261: 4889–4894.
- 24 Culbertson, S.M. et al. 2003. Paradoxical impact of antioxidants on post-Amadori glycoxidation: counterintuitive increase in the yields of pentosidine and Nepsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative. J. Biol. Chem. 278: 38384–38394.
- 25 Monnier, V.M., D.R. Sell & S. Genuth. 2005. Glycation products as markers and predictors of the progression of diabetic complications. Ann. N.Y. Acad. Sci. 1043: 567–581.
- 26 Sell, D.R. & V.M. Monnier. 2005. Ornithine is a novel amino acid and a marker of arginine damage by oxoaldehydes in senescent proteins. Ann. N.Y. Acad. Sci. 1043: 118–128.
- 27 Fioretto, P. et al. 1998. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339: 69–75.
- 28 Wu, X. et al. 2002. Alteration of substrate selectivity through mutation of two arginine residues in the binding site of amadoriase II from Aspergillus sp. Biochemistry 41: 4453–4458.
- 29 Capuano, E. et al. 2007. Studies on the effect of Amadoriase from Aspergillus fumigatus on peptide and protein glycation in vitro. J. Agric. Food Chem. 55: 4189–4195.
- 30 Sakaue, R. & N. Kajiyama. 2003. Thermostabilization of bacterial fructosyl-amino acid oxidase by directed evolution. Appl. Environ. Microbiol. 69: 139–145.
- 31 Puttaiah, S. et al. 2006. Detection of dideoxyosone intermediates of glycation using a monoclonal antibody: characterization of major epitope structures. Arch. Biochem. Biophys. 446: 186–196.
- 32 Fu, M.X. et al. 1994. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43: 676–683.
